GUÍA MANEJO ANTIRRETROVIRAL PERSONAS VIH

More documents

Recommendations

Info

infected children and adolescents. Pediatric Infect Dis J 2012;31:273-277. 107. Palladino C, Navarrro M, Soler-Palacin P, Gonzalez- Tome M, De Orye S, Espiau M, Perez S, Leon-Legal J, Mendez M, Moreno-Perez D, Fortuny C, Mur A, Pocheville I, Moreno S, Brizn V, on bealf of the CoRISpe Working Group. Off-label use of maraviroc in HIV-1 infected paediatric patients in clinical practice. AIDS 2015, 29:2155–2159 Capítulo 4 1. American College of Obstetricians and Gynecologists. ACOG Committee Opinion number 313, September 2005. The importance of preconception care in the continuum of women's health care. Obstet Gynecol. 2005;106(3):665-666. 2. Johnson K, Posner SF, Biermann J, et al. Recommendations to improve preconception health and health care—United States. A report of the CDC/ATSDR Preconception Care Work Group and the Select Panel on Preconception Care. MMWR Recomm Rep. 2006;55(RR-6):1-23. 3. Cohn SE, Umbleja T, Mrus J, Bardeguez AD, Andersen JW, Chesney MA. Prior illicit drug use and missed prenatal vitamins predict nonadherence to antiretroviral therapy in pregnancy: adherence analysis A5084. AIDS Patient Care STDS. 2008;22(1):29-40. 4. Finer LB, Zolna MR. Unintended pregnancy in the United States: incidence and disparities, 2006. Contraception. 2011;84(5):478- 485. 5. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994; 331(18):1173-80. 6. Dorenbaum A, Cunningham CK, Gelber RD, Culnane M, Mofenson L, Britto P et al. Two- dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial. Jama.2002; 288(2):189- 198. 7. Townsend CL, Cortina-Borja M, Peckham CS, de Ruiter A, Lyall H, Tookey PA. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS. 2008; 22(8):973-981. 8. Garcia PM, Kalish LA, Pitt J, Minkoff H, Quinn TC, Burchett SK et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. N Engl J Med. 1999; 341(6):394-402. 9. Ioannidis JP, Abrams EJ, Ammann A, Bulterys M, Goedert JJ, Gray L et al. Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads
36. Westling K, Pettersson K, Kaldma A, Naver L. Rapid decline in HIV viral load when introducing raltegravir-containing antiretroviral treatment late in pregnancy. AIDS Patient Care STDS. 2012;26(12):714-717. 37. Renet S, Closon A, Brochet MS, Bussieres JF, Boucher M. Increase in transaminase levels following the use of raltegravir in a woman with a high HIV viral load at 35 weeks of pregnancy. J Obstet Gynaecol Can. 2013;35(1):68-72. 38. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial. Lancet. 2002; 359(9313):1178-1186. 39. Townsend C, Cortina-Borja M, Peckman C, et all. Very low risk of mother-to-child transmission (MTCT) in women on HAART who achieve viral suppression: data from de United Kingdoom and Ireland, 2000-2006. 15th conference on retroviruses and opportunistic Infections, Boston, MA, USA3-6th February 2008. 40. Livingston EG, Hua Y, Patel K, et al. Model of delivery and infants respiratory morbidity among infants born to HIV-infected women. Obstet gynecol. 2010; 116:335-342. 41. Boer K, Nellen JF, Patel D, et al. The AmRo study: pregnancy outcome in HIV-1- infected women under effective higly active antiretroviral therapy and a policy of vaginal delivery. Br J Obstet Gynaecol. 2007; 114:148-155. 42. Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Diagnosis of HIV infection in infants and children C1-C10. February2014. 43. Burgard M1, Blanche S, Jasseron C, Descamps P, Allemon MC, Ciraru-Vigneron N, Floch C, Heller-Roussin B, Lachassinne E, Mazy F, Warszawski J, Rouzioux C. Performance of HIV-1 DNA or HIV-1 RNA tests for early diagnosis of perinatal HIV-1 infection during anti-retroviral prophylaxis. J Pediatr. 2012; 160:60-6. 44. Robinson l, Fernandez A. Clinical care of the exposed infants of HIV-infected mothers. Clin Perinatol. 2010;37:863-72. 45. Bitnun A, Samson L,Chun T-W, Kakkar F, Brophy J, Murray D y col. Early Initiation of Combination Antiretroviral Therapy in HIV-1–Infected Newborns Can Achieve Sustained Virologic Suppression With Low Frequency of CD4+ T Cells Carrying HIV in Peripheral Blood. CID 2014; 59:1012-1019 46. Haile-Selassie H, Townsend C, Tookey P. Use of neonatal postexposure prophylaxis for prevention of mother-to-child HIV transmission in the UK and Ireland. HIV Med 2011;12 : 422–427 47. Shetty A, Coovadia H, Mirochnick M et al . Safety and trough concentrations of nevirapine prophylaxis given daily, twice weekly, or weekly in breast-feeding infants from birth to 6 months. J Acquir Immune Defic Syndr 2004; 34 : 482–490. 48. British HIV Association guidelines for the management of HIV infection in pregnant women 2012 (2014 interim review).HIV Medicine (2014), 15(Suppl. 4), 1–77 49. Sollai S, Noguera-Julian A, Galli L, Fortuny C, Deyà A, de Martino M, Chiappini E. Strategies for the Prevention of Mother to Child Transmission in Western Countries. An Update. Pediatr Infect Dis J 2015; 34: S14–S30 50. Homsy J, Moore D, Barasa A et al. Breastfeeding, mother-to-child HIV tansmission, and mortality among infants born to HIVinfected women on highly active antiretroviral therapy in rural Uganda. J Acquir Immune Defic Syndr 2009; 53: 28–35. 51. Kilewo C, Karlsson K, Ngarina M et al. Prevention of mother-tochild transmission of HIV-1 through 52. breastfeeding by treating mothers with triple antiretroviral therapy in Dar es Salaam, Tanzania: the Mitra Plus Study. J Acquir Immune Defic Syndr 2009; 52: 406–416. 53. Marazzi MC, Nielsen-Saines K, Buonomo E et al. Increased infant human immunodeficiency virus-type one free survival at one year of age in sub-saharan Africa with maternal use of highly active antiretroviral therapy during breast-feeding. Pediatr Infect Dis J 2009; 28: 483–487. 54. Peltier CA, Ndayisaba GF, Lepage P et al. Breastfeeding with maternal antiretroviral therapy or formula feeding to prevent HIV postnatal mother-to-child transmission in Rwanda. AIDS 2009; 23: 2415–2423. 55. Shapiro RL, Hughes MD, Ogwu A et al. Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med 2010; 362: 2282–2294. 56. de Vincenzi I, Kesho Bora Study Group. Triple antiretroviral compared with zidovudine and single-dose 57. nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect Dis 2011; 11: 1180. 58. Chasela CS, Hudgens MG, Jamieson DJ et al. Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. NEnglJ Med 2010; 362: 2271–2281. 59. Kilewo C, Karlsson K, Massawe A et al. Prevention of mother-tochild transmission of HIV-1 through breast-feeding by treating infants prophylactically with lamivudine in Dar es Salaam, Tanzania: the Mitra Study. J Acquir Immune Defic Syndr 2008; 48: 315–323. 60. Shapiro RL, Ndung’u T, Lockman S et al. Highly Active Antiretroviral Therapy Started during Pregnancy or Postpartum Suppresses HIV-1 RNA, but Not DNA, in Breast Milk. J Infect Dis 2005; 192: 713–719. Anexo I 1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care, 34 (Suppl 1) (2011), pp. S62– S69. 2. American Diabetes Association. Standars of medical care in Diabetes-2014. Diabetes Care, 37 (Suppl 1) (2014), pp. S14– S80. 3. P. Kim, C. Woods, P. Georgoff, D. Crum, A. Rosenberg, M. Smith, et al. A1C underestimates glycemia in HIV infection. Diabetes Care, 32 (2009), pp. 1591–1593. 4. De Wit S, Sabin CA, Weber R, et al. Incidence and risk factors for new onset diabetes mellitus in HIV infected patients: the D:A:D study. Diabetes Care. 2008 Jun;31(6):1224-9. 5. Tien PC, Schneider MF, Cox C, et al. Association of HIV infection with incident diabetes mellitus: impact of using hemoglobin A1C as a criterion for diabetes. J Acquir Immune Defic Syndr. 2012 Nov 1;61(3):334-4 6. European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV [consultado 13 Ene 2013]. Disponible en: http://www.europeanaidsclinicalsociety.org/guid2/index.ht ml?ml=1 7. Documento de consenso de Gesida/Secretaría del Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana. Enero de 2014 [consultado 13 Ene 2013]. Disponible en:http://www.msssi.gob.es/ciudadanos/enfLesiones/enfTrans misibles/sida/publicaciones/profSanitarios/docConsensoTARG esidaPNSAdultos_enero2014.pdf 8. A. Muñoz-Sanz, F.F. Rodriguez-Vidigal, P. Domingo. Patogénesis de la lipodistrofia y síndromes metabólicos asociados a la infección por el <strong>VIH</strong>. Med Clin (Barc), 127 (2006), pp. 465–474. 9. P. Domingo, V. Estrada, J. Lopez-Aldeguer, F. Villaroya, E. Martinez. Fat redistribution syndromes associated with HIV-1 infection and combination antiretroviral therapy. AIDS Rev.14 (2012), pp. 112–123. 10. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP). Final report Circulation, 106 (2002), pp. 3143–3421. 11. P.S. Jellinger, D.A. Smith, A.E. Mehta, O. Ganda, Y. Handelsman, H.W. Rodbard, The AACE Task Force for Management of Dyslipidemia and Prevention of Atherosclerosis, et al. American Association of Clinical Endocrinologists’ Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. Endocr Pract, 18 (Supp 1) (2012), pp. 1–78. 12. Martin A and Emery S. Metabolic disorders and cardiovascular consequences of HIV infection and antiretroviral therapy. Exp Rev Clin Pharmacol. 2009;2:381–389. 13. Fautkenheuer G, et al. Lipid profiles for etravirine versus efavirenz in treatment-naïve patients in the randomized, double-blind SENSE trial.J Antimicrob Chemother. 2012;67:685–690. 14. Cohen C, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.Lancet. 2011;378:229–237. 15. Mills AM, et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS. 2009;23:1679–1688. 16. AACE Lipid Guideline. American Association of Clinical Endocrinologists Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. Endocr. Pract. March-April 2012; 18 (Suppl 1): S1-S78. 17. Grundy SM, et al. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004; 110: 227-239. 179
Page 2 and 3:
Las modificaciones realizadas en la
Page 4 and 5:
SECRETARÍA DE SALUD DR. JOSE RAMÓ
Page 6 and 7:
Dra. Giorgia Rubio Bravo Secretaria
Page 8 and 9:
COMITÉ DE ATENCIÓN INTEGRAL DEL C
Page 10 and 11:
PRESENTACIÓN El tratamiento antirr
Page 12 and 13:
INTRODUCCIÓN La Medicina Basada en
Page 14 and 15:
Tabla 1.1. Evaluación de las perso
Page 16 and 17:
Tabla 1.2. Evaluación de niños, n
Page 18 and 19:
Tabla 2.2. Monitoreo de laboratorio
Page 20 and 21:
CAPÍTULO 2 2. Tratamiento antirret
Page 22 and 23:
Tabla 3. Potenciales ventajas y des
Page 24 and 25:
2.2. Combinación de antirretrovira
Page 26 and 27:
Ventajas Desventajas Tabla 9. Venta
Page 28 and 29:
Tabla 11. Conducta a seguir ante la
Page 30 and 31:
Tiempo en falla Menos de 6 meses M
Page 32 and 33:
2.4. Tratamiento de rescate de la f
Page 34 and 35:
2.6. Seguimiento de las personas co
Page 36 and 37:
7. Cuando el cambio sea por un medi
Page 38 and 39:
Evento adverso o tóxico existente
Page 40 and 41:
Automedicación, incluyendo la toma
Page 42 and 43:
Factores Sociales, económicos, edu
Page 44 and 45:
2.8.2. Métodos para medir el apego
Page 46 and 47:
Categoría Estadio 3 Enfermedades o
Page 48 and 49:
En ocasiones se difiere el tratamie
Page 50 and 51:
Tabla 30. Esquemas recomendados par
Page 52 and 53:
Tabla 31. ARV utilizados en el trat
Page 54 and 55:
Raltegravir (RAL) Tableta: 400 mg -
Page 56 and 57:
Cada caso se debe individualizar y
Page 58 and 59:
3.6. Esquemas recomendados en pacie
Page 60 and 61:
1. Se sugiere que los pediatras en
Page 62 and 63:
4. Embarazo y VIH CAPÍTULO 4 El us
Page 64 and 65:
Esquema recomendado para mujeres qu
Page 66 and 67:
4.4. Profilaxis en el recién nacid
Page 68 and 69:
Profilaxis antirretroviral Edad Par
Page 70 and 71:
En la tabla 44 se describen los cri
Page 72 and 73:
momento que se descarte la infecci
Page 74 and 75:
Tabla 46. Recomendaciones sobre el
Page 76 and 77:
Disminución del consumo de alcohol
Page 78 and 79:
Tabla I-D. Manejo del colesterol LD
Page 80 and 81:
Trastornos en el metabolismo de la
Page 82 and 83:
Tabla I-J. Efecto de diversos antir
Page 84 and 85:
asal, para determinar las condicion
Page 86 and 87:
y la probabilidad de infección con
Page 88 and 89:
Tabla II-C. Esquemas preferentes y
Page 90 and 91:
Flujograma 90
Page 92 and 93:
Exposición ocupacional al VIH en t
Page 94 and 95:
ANEXO III. ABORDAJE DE OTRAS INFECC
Page 96 and 97:
Tabla III-A. Tratamiento de infecci
Page 98 and 99:
Page 100 and 101:
Page 102 and 103:
Tabla III-B. Profilaxis de infeccio
Page 104 and 105:
Tabla III-B. Profilaxis de infeccio
Page 106 and 107:
Tabla III-C. Tratamiento de infecci
Page 108 and 109:
Page 110 and 111:
Page 112 and 113:
ANEXO IV. VACUNACIÓN EN LAS PERSON
Page 114 and 115:
Esquema de vacunación recomendado
Page 116 and 117:
Influenza estacional Tabla IV-A. Va
Page 118 and 119:
Tabla IV-A. Vacunación recomendada
Page 120 and 121:
Diagnóstico de infección por VHC
Page 122 and 123:
B. Tratamiento óptimo para VHC La
Page 124 and 125:
Tabla V-G. Tratamiento de personas
Page 126 and 127:
es menor en los más jóvenes, aume
Page 128 and 129: de la replicación viral sostenida
Page 130 and 131: Tratamiento de la infección por VH
Page 132 and 133: aumento transitorio en las transami
Page 134 and 135: Tabla VI-B. Momento de inicio del t
Page 136 and 137: Tabla VI-E. Inicio del tratamiento
Page 138 and 139: Tabla VII-A. ARV disponibles en Mé
Page 140 and 141: Tabla VII-B. Uso de ARV en insufici
Page 142 and 143: Tabla VII-B. Uso de ARV en insufici
Page 144 and 145: Tabla VII-C. Efectos colaterales/t
Page 146 and 147: Tabla VII-C. Efectos colaterales/t
Page 148 and 149: Tabla VII-D. Fármacos contraindica
Page 150 and 151: Tabla. VII-E. Interacciones medicam
Page 152 and 153: Tabla VII-F. Interacciones medicame
Page 154 and 155: Tabla VII-F. Interacciones medicame
Page 156 and 157: Rifabutina Claritromicina Tabla VII
Page 158 and 159: Ácido valproico Lamotrigina Metado
Page 160 and 161: Tadalafil Vardenafil Tabla VII-G. I
Page 162 and 163: Tabla VII-H. Interacciones medicame
Page 168 and 169: SQV EFV NVP ETV TDF Tabla VII-J. In
Page 170 and 171: Tabla VII-K. Interacciones medicame
Page 172 and 173: BIBLIOGRAFÍA Capítulo 1 1. Secret
Page 174 and 175: in Mexican HIV Clinics. Open Forum
Page 176 and 177: 31. Sánchez JM, Ramos JT, Fernánd
Page 180 and 181: 18. European AIDS Clinical Society
Page 182 and 183: Centers for Disease Control and Pre
Page 184 and 185: 22. Abdool Karim SS, Naidoo K, Grob
Page 186 and 187: Nombre Adrián Flores Gaxiola Emple
Page 188: Nombre Patricia Volkow Fernández L
show all

GUÍA MANEJO ANTIRRETROVIRAL PERSONAS VIH

Create successful ePaper yourself

Delete template?

Save as template?